These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18272062)

  • 21. Dopaminergic neurons.
    Chinta SJ; Andersen JK
    Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology and pathophysiology of dopaminergic neurons.
    Hornykiewicz O
    Adv Cytopharmacol; 1971 May; 1():369-77. PubMed ID: 4950404
    [No Abstract]   [Full Text] [Related]  

  • 23. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action.
    Kim YJ; Park HJ; Lee G; Bang OY; Ahn YH; Joe E; Kim HO; Lee PH
    Glia; 2009 Jan; 57(1):13-23. PubMed ID: 18661552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
    Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V
    Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132
    [No Abstract]   [Full Text] [Related]  

  • 26. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites.
    Hastings TG; Zigmond MJ
    J Neural Transm Suppl; 1997; 49():103-10. PubMed ID: 9266419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease.
    Jankovic J; Chen S; Le WD
    Prog Neurobiol; 2005; 77(1-2):128-38. PubMed ID: 16243425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Parkinson's disease: some physiopathologic aspects and clinical practice].
    Agid Y
    Rev Prat; 1989 Mar; 39(8):641-6. PubMed ID: 2567050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Neuronal death caused by apoptosis in Parkinson disease].
    Ruberg M; France-Lanord V; Brugg B; Lambeng N; Michel PP; Anglade P; Hunot S; Damier P; Faucheux B; Hirsch E; Agid Y
    Rev Neurol (Paris); 1997 Sep; 153(8-9):499-508. PubMed ID: 9683999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent discoveries on the function and plasticity of central dopamine pathways].
    Thibault D; Kortleven C; Fasano C; Dal Bo G; Trudeau LE
    Med Sci (Paris); 2010 Feb; 26(2):165-70. PubMed ID: 20188048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results.
    Kirik D; Björklund A
    Brain; 2005 Jul; 128(Pt 7):1478-9. PubMed ID: 15980119
    [No Abstract]   [Full Text] [Related]  

  • 32. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
    Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis.
    Di Chiara G; Morelli M
    Adv Neurol; 1993; 60():102-6. PubMed ID: 8093571
    [No Abstract]   [Full Text] [Related]  

  • 34. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies.
    Gerlach M; Riederer PF
    Adv Neurol; 1999; 80():219-25. PubMed ID: 10410725
    [No Abstract]   [Full Text] [Related]  

  • 35. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 36. The dopaminergic nigrostriatal system: development, physiology, disease.
    von Bohlen Und Halbach O; Krieglstein K; Schober A; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):3. PubMed ID: 15340830
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinicopathological heterogeneity and non-dopaminergic influences on behavior in Parkinson's disease.
    Sagar HJ
    Adv Neurol; 1999; 80():409-17. PubMed ID: 10410749
    [No Abstract]   [Full Text] [Related]  

  • 38. Foxa2: the rise and fall of dopamine neurons.
    Arenas E
    Cell Stem Cell; 2008 Feb; 2(2):110-2. PubMed ID: 18371430
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Organization of the human embryonic ventral mesencephalon.
    Nelander J; Hebsgaard JB; Parmar M
    Gene Expr Patterns; 2009 Dec; 9(8):555-61. PubMed ID: 19825428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.